This episode focuses on the mission and impact of GO2 for Lung Cancer, an organization dedicated to improving the lives of people affected by lung cancer through research, advocacy, education, and direct support. The discussion explores the severity of lung cancer in the United States, the importance of early detection and access to new therapies, and the lived experience of patients and survivors. The conversation highlights how medical experts, advocates, and survivors work together to advance understanding and improve outcomes.
Guests:
Laurie Fenton Ambrose, President & CEO of GO2 for Lung Cancer
Narjust Florez, MD, Thoracic Oncologist
Karen Mostes-Withrow, Board Member and 17-Year Lung Cancer Survivor
Interview by: Mark Oppenheim
Key Points:
-
Lung cancer remains the leading cause of cancer death for both men and women.
-
Many cases are diagnosed at late stages, making early detection essential to improving survival.
-
GO2 for Lung Cancer provides trusted information, patient navigation, and support services.
-
Stigma around lung cancer continues to delay diagnosis and limit support for patients.
-
Advances in precision medicine and targeted therapies offer new treatment possibilities.
-
Access to these therapies is uneven, and many patients lack availability of the most effective options.
-
Screening eligibility and adoption remain limited despite its ability to save lives.
-
Geographic, economic, and racial disparities affect screening rates and treatment outcomes.
-
Survivor voices, such as Karen’s, highlight the challenges patients face in care, diagnosis, and public understanding.
-
Donations and awareness campaigns are vital to expanding GO2’s mission and reaching more families.
Other Points on Go2 For Lung Cancer:
The guests emphasize how stigma and misinformation remain major barriers for those affected by lung cancer. Patients are often judged or blamed, which can discourage them from seeking care or sharing their diagnosis. GO2 works to shift the narrative by reinforcing that lung cancer can affect anyone.
Medical expertise plays a central role in the conversation. Dr. Florez discusses how many patients qualify for screenings but never receive them, and how lack of access to new therapies can dramatically impact survival. Her insights highlight the importance of expanding equitable access across community hospitals and underserved regions.
Laurie Fenton Ambrose underscores the need for strong advocacy to expand funding, support research, and push for policies that improve screening, treatment, and outcomes. GO2’s work also includes helping families navigate complex systems during a difficult and emotional time.
Karen Mostes-Withrow provides the perspective of a long-term survivor. Her experiences illustrate the importance of being informed, proactive, and supported. Her insights reinforce how education, trusted information, and emotional support are essential at every stage of the lung cancer journey.